Table 2.
Clinical characteristics of breast cancer patients, safety and efficacy evaluation
| Patient No. | Age | AJCC stage | ER | PR | HER2/neu | Prior treatment
|
Best overall response | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Surgery | Chemotherapy | Radiation therapy | Hormonal therapy | |||||||
| 1 | 71 | III | + | + | + | No | Yes | Yes | Yes | N/A |
| 2 | 47 | IV | + | + | − | No | Yes | No | Yes | CR |
| 3 | 43 | III | − | − | − | No | Yes | Yes | No | PD |
| 4 | 36 | III | + | + | − | No | Yes | Yes | No | N/A |
| 5 | 40 | IV | − | + | + | Yes | Yes | Yes | Yes | PR |
| 6 | 85 | IV | − | − | − | No | No | No | No | PR |
| 7 | 78 | III | N/A | N/A | N/A | No | No | No | No | PR |
| 8 | 58 | III | − | − | − | No | No | No | No | PD |
| 9 | 66 | IV | + | + | Yes | Yes | Yes | Yes | PR | |
| 10 | 39 | IV | − | + | − | Yes | Yes | Yes | Yes | SD |
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; AJCC, American Joint Committee on Cancer; N/A, not available or not applicable; CR, complete response; PR, partial response; SD, Stable disease; PD, Progressive disease.